Prescription Opioid Formulation to Deter Extraction, Injection, Insufflation, and Smoking

NIH RePORTER · NIH · R21 · $193,750 · view on reporter.nih.gov ↗

Abstract

PROJECT SUMMARY/ABSTRACT: In the United States, there are currently more prescriptions for opioids than there are people. The number of deaths caused by drug overdoses continues to increase, with more than 60% involving prescription opioids. As a result, an estimated 42,000 people will be lost to the drug epidemic this year alone. What often begins as a temporary relief of pain can transition into an addiction that requires increased doses or a more efficient means of getting the drug into the person's system. Thus, patients have developed methods for processing the prescription pills to prepare them for alternative routes of administration such as injection, insufflation, or smoking. However, these alternative routes of administration can cause unsafe blood serum levels of the drug and lead to an overdose. Therefore, we propose to develop a novel abuse deterrent formulation (ADF) that will be uniquely designed to prevent abuse of the prescription pill. The proposal will be performed in 2 aims. The first aim will focus on the development of the ADF formulation with design aspects specifically focused on abuse through insufflation, smoking, injection and taking multiple pills. In Aim 2 we will focus on validating the design by putting the pill through a rigorous test following the procedures outlined by the FDA Abuse-Deterrent Opioids-Evaluation and Labeling guidelines. Our proposed studies will result in the development of a novel ADF formulation that will be resistant to a wide range of tampering, resulting in a safer formulation and pill design.

Key facts

NIH application ID
9893842
Project number
5R21DA048074-02
Recipient
PURDUE UNIVERSITY
Principal Investigator
Luis Solorio
Activity code
R21
Funding institute
NIH
Fiscal year
2020
Award amount
$193,750
Award type
5
Project period
2019-03-15 → 2023-02-28